Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Pr...
February 12 2020 - 4:01PM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
biopharmaceutical company, today announced that it will report
financial results and provide an update on recent progress on its
development programs post-market on February 19, 2020.
Reata’s management will host a conference call
on February 19, 2020, at 4:30 p.m. ET. The conference call
will be accessible by dialing (844) 348-3946 (toll-free domestic)
or (213) 358-0892 (international) using the access code:
1434037. The webcast link is
https://edge.media-server.com/mmc/p/jop4mn3n.
Fourth-quarter and full-year 2019 financial
results to be discussed during the call will be included in an
earnings press release that will be available on the company’s
website shortly before the call at
http://reatapharma.com/investors/ and will be available for 12
months after the call. The audio recording and webcast will
be accessible for at least 90 days after the event at
http://reatapharma.com/investors/.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone methyl
(bardoxolone) and omaveloxolone, target the important transcription
factor Nrf2 that promotes the resolution of inflammation by
restoring mitochondrial function, reducing oxidative stress, and
inhibiting pro-inflammatory signaling. Bardoxolone and
omaveloxolone are investigational drugs, and their safety and
efficacy have not been established by any agency.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:Vinny JindalVice President,
Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Media:Matt Middleman, M.D.LifeSci Public
Relations(646)
627-8384matt.middleman@lifescipublicrelations.com
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024